Wednesday, February 19, 2014
Increased Intensity of Renal Replacement Therapy Does Not Reduce Premature Mortality in Patients with AKI
Saturday, February 8, 2014
Thursday, February 6, 2014
Wednesday, February 5, 2014
The CBS Evening News (1/29, story 9, 1:45, Pelley) reported that new research suggests “a link between testosterone supplements and heart attacks.”
USA Today (1/30, Szabo) reports that the study, published in PLOS One, found that “taking testosterone therapy doubled the risk of heart attack among men over age 65 and nearly tripled the risk in younger men with a history of heart disease.” This research, “which involved 56,000 men, is the latest in a series of studies raising concerns about the heart attack risk from testosterone therapy, whose popularity has ballooned in recent years.”
On its website, NBC News (1/30, Fox) reports that “to be sure,” the researchers “compared the men getting testosterone to those getting prescriptions for erectile dysfunction drugs, as the two groups are similar in many ways.” The investigators found that the ED medications “only very slightly raised the risk of heart attack.”
The New York Times (1/30, O'Connor) “Well” blog reports, “By itself, the new study, which was not a randomized trial...’may not tell us very much,’ said Dr. Michael Lauer, the director of cardiovascular sciences at the National Heart, Lung and Blood Institute, who was not involved in the study.” However, added Dr. Lauer, “when you put this together with the rest of the medical literature, this tells us that we potentially have a problem.” Meanwhile, “in a statement, Andrea Fischer, an F.D.A. spokeswoman, said the agency was reviewing the new findings.”
On its website, TIME (1/30, Sifferlin) reports that although it is unclear “why testosterone can harm the heart, some studies suggest that it can lower levels of HDL, or good cholesterol, and therefore increase the risk of heart disease.”
Meanwhile, on the CBS News (1/30) website, CBS’ Dr. Jon Lapook writes that a “possible way testosterone might be causing problems is by increasing clotting within arteries supplying the heart.”
Forbes (1/30) contributor Ed Silverman points out that these “findings come amid years of aggressive promotion of testosterone treatments.” Research “published last fall in the Journal of the American Medical Association noted that annual prescriptions for these elixirs rose more than five-fold from 2000 to 2011, reaching 5.3 million prescriptions.”
The Los Angeles Times (1/30, Healy) “Science Now” blog also covers the story.
Patients with rheumatoid arthritis (RA) are more likely to develop reduced kidney function over time, and cardiovascular disease (CVD) appears to play a role. AnAJKD study of 813 patients with RA and 813 non-RA individuals found the 20-year cumulative incidence of reduced kidney function was higher in patients with RA compared with non-RA participants for eGFR below 60mL/min/1.73m² (25% vs. 20%), but not eGFR below 45mL/min/1.73m² (9% vs. 10%). In RA patients, those with CVD at baseline were 77% more likely to experience a drop in kidney function to below 60 mL/min/1.73m².
ABC World News (1/28, story 6, 0:25, Sawyer) reports in its broadcast that an FDA report said naproxen found in Bayer AG’s Aleve painkiller could be a safer alternative for people with heart diseases compared with its rivals. “The FDA found the key ingredient may provide a lower risk of heart attack and stroke than a rival medication, Ibuprofen,” ABC News said.
The Wall Street Journal (1/29, Burton, Dooren, Subscription Publication) reports proof that naproxen, found in Bayer AG’s Aleve and other generic medications, is safer comes from a number of studies the FDA reviewed since 2005.
The AP (1/29, Perrone) reports FDA staffers backed “relabeling naproxen to emphasize its safety.” The labeling changes “could make Aleve and other naproxen drugs the first choice for patients with a higher risk for heart problems,” according to Ira Loss, a pharmaceutical analyst with Washington Analysis.
Bloomberg News (1/28, Edney) reports the FDA is asking advisers to consider whether to block the ongoing safety study of Pfizer Inc. arthritis medicine Celebrex (celecoxib) “compared with ibuprofen and naproxen” since naproxen “is seen as safer.” Bloomberg also notes that a study published in medical journal Lancet last year also showed naproxen was safer compared with other painkillers.
The Wall Street Journal (1/10, Loftus, Subscription Publication) reports that the study, which included more than 280 participants, was funded by the National Institute of Diabetes and Digestive and Kidney Diseases.
The AP (1/10) reports that the trial “compared a daily 25-millligram oral dose of obeticholic acid with a placebo.” Those given the medication “for 72 weeks were more likely to have a significant reduction in disease.” Also covering the story are Bloomberg News (1/10, Armstrong), Reuters(1/10, Manocha) and Forbes (1/10, Solomon).
The New York Times (12/19, A23, Kolata, Subscription Publication) reports that “new guidelines suggest that people over 60 can have a higher blood pressure than previously recommended before starting treatment to lower it.” The guidelines committee, “composed of 17 academics, was tasked with updating guidelines last re-examined a decade ago.” The recommendations were “published online on Wednesday in The Journal of the American Medical Association.”
The AP (12/19) reports that “the panel completed its work earlier this year, around the same time that the National Heart, Lung and Blood Institute announced that it was getting out of the guidelines business and turning the job over to the American Heart Association and American College of Cardiology.”
The Wall Street Journal (12/19, A2, Winslow, Subscription Publication) points out that neither the American College of Cardiology nor the American Heart Association vetted the document, nor did the NHLBI.
The Los Angeles Times (12/19, Kaplan) “Science Times” blog reports that “rather than aim for a target blood pressure of 140/90 mm Hg, the target will be relaxed slightly to 150/90 mm Hg, according to” the “new guidelines.” The guidelines’ authors “emphasized that they were not changing the definition of high blood pressure.” Instead, “they are recognizing that data from randomized clinical trials do not show that using drugs to nudge down systolic blood pressure from 150 to 140 provides any health benefit.”
Bloomberg News (12/19, Cortez) reports that individuals aged “60 and older were focused on in the guidelines because they ‘are a unique population and we are concerned about the number of medications that may be required,’ said Paul James, the lead author of the article.”
According to the Boston Globe (12/19, Kotz), “a number of cardiologists...complained that the new guideline was not issued by any major medical group or government entity.”
Harlan Krumholz, MD, discusses the guidelines in the New York Times (12/19) “Well” blog. Also covering the story are CNN (12/19, Willingham), MedPage Today (12/19, Neale), and HealthDay (12/19, Thompson).